Real-world progression-free survival and overall survival of palbociclib plus endocrine therapy (ET) in Japanese patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer in the first-line or second-line setting: an observational study

CONCLUSION: The addition of palbociclib to ET was effective for treating HR+/HER2- ABC in Japanese routine clinical practice.PMID:38642245 | DOI:10.1007/s12282-024-01575-5

Source: Breast Cancer - April 20, 2024 Category: Cancer & Oncology Authors: Tetsuhiro Yoshinami Shigenori E Nagai Masaya Hattori Takuho Okamura Kenichi Watanabe Takahiro Nakayama Hiroko Masuda Michiko Tsuneizumi Daisuke Takabatake Michiko Harao Hiroshi Yoshino Natsuko Mori Hiroyuki Yasojima Chiya Oshiro Madoka Iwase Miki Yamaguch Source Type: research